Effect of Jiedu Huayu Tongfu prescription on intestinal flora in patients with hepatitis B cirrhosis with liver-gallbladder damp-heat syndrome

Jiangkai LIU; Yameng NIU; Suling LI; Qingliang MA; Jiangwen ZHANG; Yaru ZHANG; Bingqian LI

doi:10.3969/j.issn.1001-5256.2022.04.016

Volume 38 Issue 4

Apr. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(4): 821-827

PDF( 3527 KB)

Effect of Jiedu Huayu Tongfu prescription on intestinal flora in patients with hepatitis B cirrhosis with liver-gallbladder damp-heat syndrome

DOI: 10.3969/j.issn.1001-5256.2022.04.016

1.
Spleen, Stomach and Hepatobiliary Department, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China
2.
The First Clinical Medical College of Henan University of Chinese medicine, Zhengzhou 450000, China

Research funding:

Joint Fund of National Natural Science Foundation of China (U1504825);

Key Scientific Research Project Plan of Colleges and Universities in Henan Province (20A360014);

Henan Provincial Top Talent Training Program of Traditional Chinese Medicine (Yuwei Zhongyi Han [2021] No.15)

More Information

Corresponding author: LIU Jiangkai, xmlc001@126.com (ORCID: 0000-0002-1529-5089)
Received Date: 2021-08-25
Accepted Date: 2021-11-05
Published Date: 2022-04-20

Abstract

Abstract

Objective To investigate the regulatory effect of Jiedu Huayu Tongfu prescription on intestinal homeostasis in patients with hepatitis B cirrhosis with liver-gallbladder damp-heat syndrome, as well as its effect on endotoxin, inflammatory factors, and cellular immune function. Methods A total of 72 patients who attended The First Affiliated Hospital of Henan University of Chinese Medicine from June 2019 to January 2021 and met the diagnostic and inclusion criteria were enrolled as subjects and then randomly divided into observation group and control group, with 36 patients in each group. In the treatment group, 2 patients were lost to follow-up, 2 patients were excluded, and 32 patients completed the study; in the control group, 2 patients were lost to follow-up, 1 patient was excluded, and 33 patients completed the study. In addition to the basic treatment including antiviral therapy and liver-protecting treatment, the patients in the observation group were given Jiedu Huayu Tongfu granules, and those in the control group were given oral administration of Bifidobacterium tetravaccine tablets; the course of treatment was 4 weeks for both groups. The 16S rDNA sequencing technique was used for sequencing of fecal flora, and the two groups were measured in terms of the changes in liver function [alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), and albumin (Alb)], endotoxin (ET), levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), and T lymphocyte subsets (CD3⁺T, CD4⁺T, CD8⁺T, and CD4⁺/CD8⁺) after treatment. For normally distributed continuous data with homogeneity of variance, the paired t-test was used for comparison within each group, and the independent samples t-test was used for comparison between two groups; the Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data. The chi-square test was used for comparison of categorical data. Results The observation group had a significantly higher overall response rate than the control group (87.5% vs 60.6%, χ²=-2.299, P=0.022). After treatment, both groups had significant reductions in ALT, AST, and TBil and a significant increase in Alb (all P < 0.05), and compared with the control group, the observation group had a significantly greater reduction in TBil (Z=-2.165, P=0.030). After treatment, both groups had significant improvements in the levels of CD3⁺T, CD4⁺T, and CD4⁺/CD8⁺, and the observation group had significantly greater improvements than the control group (Z=-2.146, -2.940, and 3.157, P=0.032, 0.003, and 0.002). After treatment, both groups had significant reductions in the levels of TNF-α, IL-6, and ET, and the observation group had significantly greater reductions than the control group (Z=-2.139, -1.982, and -2.062, P=0.032, 0.048, and 0.043). Both groups had an increase in the number of operational taxonomic units after treatment. As for the abundance of intestinal flora at the phylum level, the observation group had a significant increase in the abundance of Firmicutes and a significant reduction in the abundance of Bacteroidetes after treatment (Z=-3.181 and -2.215, P=0.001 and 0.027); compared with the control group, the observation group had significantly greater increases in the abundance of Firmicutes and Cyanobacteria and significantly greater reductions in the abundance of Bacteroidetes, Cercozoa, and ε-Proteobacteria (allP < 0.05). At the genus level, the observation group had a significant increase in the abundance of Bifidobacterium after treatment (Z=-2.045, P=0.041). The alpha-diversity analysis showed that the observation group had significant increases in Chao1 and Ace indices after treatment (t=-4.263 and -3.328, P=0.001 and 0.005) and a significantly greater increase in Ace index than the control group (t=2.292, P=0.030). The beta-diversity analysis showed that the two groups had a similar composition of flora without significant difference (all P > 0.05). Conclusion Jiedu Huayu Tongfu prescription, in combination with etiological and basic treatments, can alleviate clinical symptoms, reduce liver injury, and improve cellular immune function in patients with hepatitis B cirrhosis with liver-gallbladder damp-heat syndrome. Jiedu Huayu Tongfu prescription can improve the imbalance of intestinal flora by increasing the abundance of the probiotic bacteria such as Firmicutes, Lactobacillus, and Bifidobacterium and the pathogenic bacteria such as Bacteroidetes and Cercozoa, and its effect in further improving liver and immune function may be associated with the regulation of intestinal microecology.
- Hepatitis B,
- Liver Cirrhosis,
- Gut Microbiota,
- Damp Heat Syndrome Of Liver And Gallbladder,
- Jiedu Huayu Tongfu Recipe

FullText(HTML)

References(21)

References

[1]	SANTIAGO A, POZUELO M, POCA M, et al. Alteration of the serum microbiome composition in cirrhotic patients with ascites[J]. Sci Rep, 2016, 6: 25001. DOI: 10.1038/srep25001.
[2]	MUÑOZ L, BORRERO MJ, U ' BEDA M, et al. Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis[J]. Hepatology, 2019, 70(3): 925-938. DOI: 10.1002/hep.30349.
[3]	LIU JK, ZHAO WX, LIU QH, et al. Effect of Jiedu Huayu Tongfu Recipe on endotoxin and inflammatory factors in patients with alcoholic liver cirrhosis[J]. China J Tradit Chin Med Pharma, 2017, 32(12): 5668-5671. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201712115.htm 刘江凯, 赵文霞, 刘巧红, 等. 解毒化瘀通腑方对酒精性肝硬化患者内毒素及炎性因子的影响[J]. 中华中医药杂志, 2017, 32(12): 5668-5671. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201712115.htm
[4]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[5]	Branch of Hepatobiliary Diseases, Chinese Association of Chinese Medicine. The standards of traditional Chinese medicine syndrome differentiation for viral hepatitis[J]. J Clin Hepatol, 2017, 33(10): 1839-1846. DOI: 10.3969/j.issn.1001-5256.2017.10.002. 中华中医药学会肝胆病分会. 病毒性肝炎中医辨证标准[J]. 临床肝胆病杂志, 2017, 33(10): 1839-1846. DOI: 10.3969/j.issn.1001-5256.2017.10.002.
[6]	ZHENG XY. Guiding principles for clinical research of new traditional Chinese medicine (Trial)[M]. Beijing: China Medical Science and Technology Press, 2002. 郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002.
[7]	MINEMURA M, SHIMIZU Y. Gut microbiota and liver diseases[J]. World J Gastroenterol, 2015, 21(6): 1691-1702. DOI: 10.3748/wjg.v21.i6.1691.
[8]	WANG WF, CAO JB, FAN GR, et al. Meta analysis of probiotics in patients with liver cirrhosis[J]. Beijing Med J, 2015, 37 (3): 213-219. DOI: 10.15932/j.0253-9713.2015.3.005. 王伟芳, 曹建彪, 范公忍, 等. 益生菌在肝硬化患者应用的Meta分析[J]. 北京医学, 2015, 37(3): 213 -219. DOI: 10.15932/j.0253-9713.2015.3.005.
[9]	SOLÉ C, GUILLY S, DA SILVA K, et al. Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: Relationship with acute-on-chronic liver failure and prognosis[J]. Gastroenterology, 2021, 160(1): 206-218. e13. DOI: 10.1053/j.gastro.2020.08.054.
[10]	MARTINS M, BATISTA A, BRITO Y, et al. Effect of remote ischemic preconditioning on systemic toxicity and ototoxicity induced by cisplatin in rats: Role of TNF-α and Nitric Oxide[J]. ORL J Otorhinolaryngol Relat Spec, 2017, 79(6): 336-346. DOI: 10.1159/000485514.
[11]	ZHANG W, PENG Q. Relationship between intestinal flora and liver function and serum inflammatory factors in patients with hepatitis B cirrhosis[J]. Mod Digest Interv, 2020, 25(2): 158-162. DOI: 10.3969/j.issn.1672-2159.2020.02.006. 张雯, 彭琼. 乙肝肝硬化患者肠道菌群与肝功能及血清炎症因子水平的关系[J]. 现代消化及介入诊疗, 2020, 25(2): 158-162. DOI: 10.3969/j.issn.1672-2159.2020.02.006.
[12]	LARIO M, MUÑOZ L, UBEDA M, et al. Defective thymopoiesis and poor peripheral homeostatic replenishment of T-helper cells cause T-cell lymphopenia in cirrhosis[J]. J Hepatol, 2013, 59(4): 723-730. DOI: 10.1016/j.jhep.2013.05.042.
[13]	MUNOZ L, ALBILLOS A, NIETO M, et al. Mesenteric Th1 polarization and monocyte TNF-alpha production: First steps to systemic inflammation in rats with cirrhosis[J]. Hepatology, 2005, 42(2): 411-419.
[14]	MCGOVERN BH, GOLAN Y, LOPEZ M, et al. The impact of cirrhosis on CD4⁺ T cell counts in HIV-seronegative patients[J]. Clin Infect Dis, 2007, 44(3): 431-437. DOI: 10.1086/509580.
[15]	ZENG Y, CHEN S, FU Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Viral Hepat, 2020, 27(2): 143-155. DOI: 10.1111/jvh.13216.
[16]	GUO XX, HU N, LIAN XX, et al. Features of intestinal flora imbalance in patients with liver cirrhosis and related driving factors[J]. J Clin Hepatol, 2020, 36(7): 1527-1533. DOI: 10.3969/j.issn.1001-5256.2020.07.016. 郭晓霞, 胡娜, 廉晓晓, 等. 肝硬化患者肠道菌群失调的特征及驱动因子分析[J]. 临床肝胆病杂志, 2020, 36(7): 1527-1533. DOI: 10.3969/j.issn.1001-5256.2020.07.016.
[17]	ZENG Y, CHEN S, FU Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Viral Hepat, 2020, 27(2): 143-155.
[18]	ABENAVOLI L, SCARPELLINI E, COLICA C, et al. Gut microbiota and obesity: A role for probiotics[J]. Nutrients, 2019, 11(11): 2690. DOI: 10.3390/nu11112690.
[19]	SHEN ZH, ZHU CX, QUAN YS, et al. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation[J]. World J Gastroenterol, 2018, 24(1): 5-14. DOI: 10.3748/wjg.v24.i1.5.
[20]	CAO H, WU DS, ZHANG Y, et al. Effects of shaoyao decoction on intestinal flora of ulcerative colitis rats based on high-throughput sequencing technology[J]. Chin J Inf Tradit Chin Med, 2021, 28(1): 61-66. DOI: 10.19879/j.cnki.1005-5304.202006249. 曹晖, 吴东升, 张彧, 等. 基于高通量测序技术研究芍药汤对溃疡性结肠炎大鼠肠道菌群的影响[J]. 中国中医药信息杂志, 2021, 28(1): 61-66. DOI: 10.19879/j.cnki.1005-5304.202006249.
[21]	ZHANG F, LEE J, LIANG S, et al. Cyanobacteria blooms and non-alcoholic liver disease: evidence from a county level ecological study in the United States[J]. Environ Health, 2015, 14: 41. DOI: 10.1186/s12940-015-0026-7.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (525) PDF downloads(48)

Effect of Jiedu Huayu Tongfu prescription on intestinal flora in patients with hepatitis B cirrhosis with liver-gallbladder damp-heat syndrome

DOI: 10.3969/j.issn.1001-5256.2022.04.016

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effect of Jiedu Huayu Tongfu prescription on intestinal flora in patients with hepatitis B cirrhosis with liver-gallbladder damp-heat syndrome

DOI: 10.3969/j.issn.1001-5256.2022.04.016

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content